ACM
CRSP icon

Accent Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Accent Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60
Closed -$3.15K – 346
2025
Q4 		$3.15K Hold
60
– – ﹤0.01% 330
2025
Q3 		$3.89K Buy
+60
New +$3.44K ﹤0.01% 342

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Accent Capital Management's CRSP Position: Q1 2026 in Review

Accent Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 60 shares — an estimated $3.15K sold.

Accent Capital Management first reported a position in CRSP in Q3 2025 and held it in 2 quarters. The position peaked at $3.89K in Q3 2025. 489 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Accent Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Accent Capital Management sold 60 CRISPR Therapeutics shares in Q1 2026, an estimated $3.15K.
  • Accent Capital Management first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 2 quarters.
  • Accent Capital Management's CRISPR Therapeutics position peaked at $3.89K in Q3 2025.
  • 489 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.